ABSTRACT
INTRODUCTION: This study investigates the incidence of extrahepatic perfusion and incomplete hepatic perfusion at intraoperative methylene blue testing and on postoperative nuclear imaging in patients undergoing hepatic arterial infusion pump (HAIP) chemotherapy. METHODS: The first 150 consecutive patients who underwent pump implantation in the Netherlands were included. All patients underwent surgical pump implantation with the catheter in the gastroduodenal artery. All patients underwent intraoperative methylene blue testing and postoperative nuclear imaging (99mTc-Macroaggregated albumin SPECT/CT) to determine perfusion via the pump. RESULTS: Patients were included between January-2018 and December-2021 across eight centers. During methylene blue testing, 29.3% had extrahepatic perfusion, all successfully managed intraoperatively. On nuclear imaging, no clinically relevant extrahepatic perfusion was detected (0%, 95%CI: 0.0-2.5%). During methylene blue testing, 2.0% had unresolved incomplete hepatic perfusion. On postoperative nuclear imaging, 8.1% had incomplete hepatic perfusion, leading to embolization in only 1.3%. CONCLUSION: Methylene blue testing during pump placement for intra-arterial chemotherapy identified extrahepatic perfusion in 29.3% of patients, but could be resolved intraoperatively in all patients. Postoperative nuclear imaging found no clinically relevant extrahepatic perfusion and led to embolization in only 1.3% of patients. The role of routine nuclear imaging after HAIP implantation should be studied in a larger cohort.
Subject(s)
Hepatic Artery , Infusions, Intra-Arterial , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Agents/administration & dosage , Hepatic Artery/diagnostic imaging , Incidence , Infusion Pumps, Implantable , Liver Circulation , Liver Neoplasms/surgery , Methylene Blue/administration & dosage , Netherlands/epidemiology , Retrospective Studies , Single Photon Emission Computed Tomography Computed Tomography , Technetium Tc 99m Aggregated Albumin/administration & dosageABSTRACT
PURPOSE: To characterize estimated mean absorbed tumor dose (ADT), objective response (OR), and estimated target dose of hepatocellular carcinoma (HCC) after resin microsphere yttrium-90 (90Y) radioembolization using partition dosimetry. MATERIALS AND METHODS: In this retrospective, single-center study, multicompartment dosimetry of index tumors receiving 90Y radioembolization between October 2015 and June 2022 was performed using a commercial software package and pretreatment technetium-99m macroaggregated albumin single photon emission computed tomography (SPECT)/computed tomography (CT). In total, 101 patients with HCC underwent 102 treatments of 127 index tumors. Patients underwent imaging every 2-3 months after treatment to determine best response per modified Response Evaluation Criteria in Solid Tumors (mRECIST). Best response was defined as the greatest response category per mRECIST and categorized as OR or nonresponse (NR). A Cox proportional hazards model evaluated the probability of tumor OR and progression-free survival using ADT. RESULTS: The median follow-up period was 148 days (interquartile range [IQR], 92-273 days). The median ADT of OR was 141.9 Gy (IQR, 89.4-215.8 Gy) compared with the median ADT of NR treatments of 70.8 Gy (IQR, 42.0-135.3 Gy; P < .001). Only ADT was predictive of response (hazard ratio = 2.79 [95% confidence interval {CI}: 1.44-5.40]; P = .003). At 6 months, an ADT of 157 Gy predicted 90.0% (95% CI: 41.3%-98.3%) probability of OR. At 1 year, an ADT of 157 Gy predicted 91.6% (95% CI: 78.3%-100%) probability of progression-free survival. Partition modeling and delivered activity were predictive of progression (P = .021 and P = .003, respectively). CONCLUSIONS: For HCC treated with resin microspheres, tumors receiving higher ADT exhibited higher rates of OR. An ADT of 157 Gy predicted 90.0% OR at 6 months.
Subject(s)
Carcinoma, Hepatocellular , Embolization, Therapeutic , Liver Neoplasms , Microspheres , Predictive Value of Tests , Radiopharmaceuticals , Single Photon Emission Computed Tomography Computed Tomography , Technetium Tc 99m Aggregated Albumin , Yttrium Radioisotopes , Humans , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/therapy , Carcinoma, Hepatocellular/radiotherapy , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/radiotherapy , Liver Neoplasms/therapy , Liver Neoplasms/pathology , Liver Neoplasms/mortality , Retrospective Studies , Yttrium Radioisotopes/administration & dosage , Yttrium Radioisotopes/adverse effects , Male , Female , Middle Aged , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/adverse effects , Aged , Embolization, Therapeutic/adverse effects , Technetium Tc 99m Aggregated Albumin/administration & dosage , Treatment Outcome , Time Factors , Radiotherapy Planning, Computer-Assisted , Aged, 80 and over , Software , Radiotherapy Dosage , AdultABSTRACT
INTRODUCTION: The classical lymphoscintigraphic investigations of lower-limb lymphatic edema [LLLE] sometimes reveal either no or few lymph nodes [LNs] at the root of the limb[s] and/or in the abdomen. The aim of the present paper is to report the results of performing one additional injection at the root of the edematous limb[s] to force the visualization of the LNs and/or to demonstrate the collateral lymphatic pathways in such patients. METHODS AND FINDINGS: We retrospectively reviewed our database and found 99 patients [44 primary LLLE with 47 limbs injected and 55 with LLLE secondary to treatments for cancer with 64 limbs injected] where such an additional injection had been performed. In the 43 LLLE patients where no LNs were seen at the end of the classical exam [15 primary LLLE and 28 secondary LLLE], the extra injection showed lymphatic drainage toward LN[s] in all except 3 and when at least one LN was seen, the injection showed lymphatic drainage in every case toward the same ipsilateral [inguinal and/or iliac] LNs [as shown by the classical injection] and/or toward additional LNs. In 40.7% of patients, we observed one or more additional lymphatic pathways: prepubic superficial lymphatic vessels [LV] crossing the midline anteriorly toward contralateral inguinal LNs in 21 [18.9%], "posterior" LV [toward contralateral inguinal LNs and/or ipsi- or contralateral lumbo-aortic and/or para-renal LNs] in 14 [12.6%], but deep LV toward the ipsilateral common iliac LNs passing between the gluteal muscles in 32 [28.8%]. CONCLUSION: Our work pinpoints one limitation of classical bipedal radionuclide lymphangiography. In patients with primary and secondary LLLE where inguinal and/or iliac LNs cannot be seen on bipedal radionuclide lymphangiography, this additional injection reveals the true lympho-nodal status and shows unexpected collateral lymphatic pathways in 40% of cases. Such information is of the utmost importance in LLLE management and its acquisition is consequently recommended in these patients.
Subject(s)
Lymphatic Vessels/diagnostic imaging , Lymphedema/diagnosis , Lymphoscintigraphy/methods , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Pentetate/administration & dosage , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Inguinal Canal , Injections/statistics & numerical data , Lower Extremity , Lymph Nodes , Lymphedema/etiology , Lymphedema/therapy , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
ANTECEDENTES: En cumplimiento del inciso e, sobre nuestras funciones como UFETS, que dice: "Evaluar las tecnologías sanitarias ya existentes en la entidad, y proponer estrategias para su uso eficiente y/o reposición", realizamos esta revisión rápida sobre la utilidad del nanocoloide de albumina combinado con la tinción de "patent blue" en la detección de ganglio centinela en pacientes con tumoración maligna en la región mamaria, vulvar o melanoma cutáneo. ESTRATEGIA DE BÚSQUEDA DE INFORMACIÓN: Pregunta Clínica: En pacientes con enfermedad oncológica ¿Cuál es la utilidad del nanocoloide de albumina Tc-99m combinado con la tinción de "patent blue" para la detección del ganglio centinela? Recolecciòn de los manuscritos a revisar: Tipos de estudios: La estrategia de búsqueda sistemática de información científica para el desarrollo del presente informe se realizó siguiendo las recomendaciones de la Pirámide jerárquica de la evidencia propuesta por Haynes y se consideró los siguientes estudios: umarios y guías de práctica clínica. Revisiones sistemáticas y/o meta-análisis. Ensayos Controlados Aleatorizados (ECA). Estudios Observacionales (cohortes, caso y control, descriptivos). No hubo limitaciones acerca de la fecha de publicación o el idioma para ningún estudio. Fuentes de información: De acceso libre . ases de datos: Pubmed y Cochrane. DISCUSIÓN: En base a los estudios expuesto se ha evidenciado que se avala que el uso de la inclusión de la estrategia combinada (Uso del nanocoloide de albumina Tc99m como parte de la linfogammagrafía y posteriormente el uso de "patent blue" durante la biopsia) para la detección y extirpación del ganglio centinela sobre todo en los tipos de cáncer de vulva, mama y melanoma cutáneo. La estrategia combinada permite tener valores de sensibilidad superiores a 95% y razones de verosimilitud positiva por encima de 10. Además, lo más resaltante es que permiten disminuir los falsos negativos hasta en menos del 5% de los casos. CONCLUSIONES: En el Instituto Nacional de Enfermedades Neoplásicas se realizan anualmente aproximadamente entre 800 a 900 intervenciones que requieren la detección del ganglio centinela por Tc-900m con albumina sérica humana. Se realizó una búsqueda sistemática y una búsqueda dirigida de la evidencia para evaluar la utilidad del Tc-900m con albumina sérica humana en pacientes con tumoraciones malignas de vulva, mama y melanoma cutáneo en quienes se va a identificar la presencia de ganglio centinela. Se encontraron 06 guías de las principales sociedades científicas que abordan el tema; una revisión sistemática, una revisión no sistemática y 03 estudios prospectivos (Dentro de ellos un Ensayo Clínico Aleatorizado). Con respecto a las guías, se ha encontrado que todas avalan el uso de coloides unidos a Tc-99m e incluso las guías de la sociedad europea de medicina nuclear menciona que el coloide de albumina sérica humana es el preferido en Europa. Con respecto a la revisión sistemática y los estudios primarios se encontró valores aceptables de sensibilidad y una baja cantidad de falsos negativos lo cual permite mejorar la exactitud diagnóstica del ganglio centinela en los cánceres de vulva, mama y melanoma cutáneo. Con respecto a la adquisición, está disponible a nivel nacional y cuenta con más de 10 años en el mercado. Además, cada unidad puede ser usado hasta en 05 pacientes. Finalmente, en base a la evidencia encontrada tanto a nivel internacional como a nivel nacional el panel establece que la intervención de coloide de albumina sérica humana más Tc-99m y combinada con "patent blue" es útil en la detección del ganglio centinela de neoplasias de mama, vulva y melanoma; además, disminuye la cantidad de falsos negativos. Por lo cual, se aprueba su uso a nivel institucional.
Subject(s)
Humans , Technetium Tc 99m Aggregated Albumin/administration & dosage , Sentinel Lymph Node Biopsy/instrumentation , Skin Neoplasms/pathology , Vulvar Neoplasms/pathology , Breast Neoplasms/pathology , Cost-Benefit AnalysisABSTRACT
Patients with severe acute liver injury (SLI) usually recover spontaneously. However, some SLI patients progress to acute liver failure with varying degrees of hepatic encephalopathy. Acute liver failure is associated with high mortality and can be substantially reduced by liver transplantation. Therefore, distinguishing SLI patients who might progress to acute liver failure and are at a risk of death is important when evaluating patients needing liver transplantation. The present study aimed to determine whether technetium-99m-diethylenetriaminepentaacetic acid galactosyl human serum albumin (Tc-99m GSA) scintigraphy can predict the prognosis of patients with SLI. This prospective observational study included 69 SLI patients. The accuracy of Tc-99m GSA for predicting death or liver transplantation for 6 months was assessed. Between the two groups of patients stratified based on the cut-off values from the receiver operating characteristic curves, 6-month transplant-free survival was compared. Sixteen (23.2%) patients died or underwent liver transplantation from admission (poor outcome). The hepatic accumulation index was calculated by dividing the radioactivity of the liver region of interest by that of the liver-plus-heart region of interest at 15 min (i.e., LHL15). The LHL15 in the 16 patients (0.686) was significantly lower than that in survivors (0.836; P < 0.0001). The optimal LHL15 cut-off for distinguishing poor outcome and survival was 0.737 with a sensitivity of 81.3%, specificity of 88.7%, and area under the curve of 0.907 (95% CI, 0.832-0.981). When patients were divided into two groups based on the LHL15 cut-off value, the 6-month transplant-free survival was significantly lower in patients with an LHL15 level ≤ 0.737. Tc-99m GSA scintigraphy may help predict the prognosis of patients with SLI.
Subject(s)
Hepatic Encephalopathy/diagnosis , Liver Failure, Acute/diagnosis , Liver/diagnostic imaging , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Pentetate/administration & dosage , Adult , Aged , Hepatectomy , Hepatic Encephalopathy/diagnostic imaging , Hepatic Encephalopathy/pathology , Humans , Liver/injuries , Liver/pathology , Liver/surgery , Liver Failure, Acute/diagnostic imaging , Liver Failure, Acute/pathology , Liver Failure, Acute/therapy , Liver Function Tests , Liver Transplantation/standards , Male , Middle Aged , Prognosis , Radionuclide Imaging , Radiopharmaceuticals/administration & dosageABSTRACT
BACKGROUND/AIM: Intraarterial Technetium-99m-Macroaggregated Albumin (99mTc-MAA) administration is an established method to predict particle distribution prior to radioembolization. This study aimed to analyse the impact of intraarterial administration of 99mTc-MAA on changes in liver-specific laboratory parameters and to assess whether such changes are associated with post-radioembolization hepatotoxicity. PATIENTS AND METHODS: A total of 202 patients treated with radioembolization received prior mapping angiography with 99mTc-MAA administration. All patients underwent clinical and laboratory examinations, including liver-specific parameters at certain times before and after mapping angiography/99mTc-MAA administration, as well as before radioembolization and during follow-up. RESULTS: Bilirubin increased temporarily after 99mTc-MAA administration (p<0.001), but was not clinically relevant, and returned close to the initial value before radioembolization. These changes showed no association with subsequent postradioembolic hepatotoxicity or shortened overall survival. CONCLUSION: 99mTc-MAA administration results in a significant, however, not clinically relevant transient increase in bilirubin levels, which does not provide a predictive value for subsequent radioembolization outcome or postradioembolic hepatotoxicity.
Subject(s)
Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , Embolization, Therapeutic/adverse effects , Liver Neoplasms/complications , Liver Neoplasms/therapy , Radiopharmaceuticals/adverse effects , Technetium Tc 99m Aggregated Albumin/adverse effects , Adult , Aged , Aged, 80 and over , Computed Tomography Angiography , Disease Management , Embolization, Therapeutic/methods , Female , Humans , Liver Function Tests , Male , Middle Aged , Prognosis , Radiopharmaceuticals/administration & dosage , Retrospective Studies , Technetium Tc 99m Aggregated Albumin/administration & dosage , Treatment OutcomeABSTRACT
PURPOSE: To evaluate whether the recalculation of lung shunt fraction (LSF) is necessary prior to next-stage or same lobe repeat radioembolization. MATERIALS AND METHODS: Retrospective chart review was performed for patients who underwent radioembolization between February 2008 and December 2018. Eighty of 312 patients had repeat mapping angiograms and LSF calculations. A total of 160 LSF calculations were made using planar imaging (155, [97%]) and single-photon emission computed tomography (5 [3%]) technetium-99m macroaggregated albumin hepatic arterial injection imaging. The mean patient age was 61.8 years ± 12.7; 69 (86%) patients had metastatic disease and 11 (14%) had hepatocellular carcinoma. RESULTS: Patients had a median LSF of 5% (interquartile range [IQR] 3%-9%) with a median absolute difference of 1.25 (IQR 0.65-3.4) and a median of 76 days (IQR 42.5-120 days) between repeat LSF calculations. There was a median change in LSF of 0.2% between mapping studies (P = .11). There was no statistical significance between the repeat LSFs regardless of the arterial distribution (P = .79) or between tumor types (P = .75). No patients exceeded lung dose limits using actual or predicted prescribed dose amounts. The actual median lung dose was 2.6 Gy (IQR 1.8-4.4 Gy, maximum = 20.5) for the first radioembolization and 2.0 Gy (IQR 1.3-3.7 Gy, maximum = 10.1) for the second radioembolization. CONCLUSIONS: No significant difference in LSF was identified between different time points and arterial distributions within the same patient undergoing repeat radioembolization. In patients who receive well under 30-Gy lung dose for the initial treatment and a 50-Gy cumulative lung dose, repeat radioembolization treatments in the same patient may not require a repeat LSF calculation.
Subject(s)
Angiography , Carcinoma, Hepatocellular/therapy , Embolization, Therapeutic , Liver Neoplasms/therapy , Lung/diagnostic imaging , Radiation Pneumonitis/prevention & control , Radiopharmaceuticals/administration & dosage , Single Photon Emission Computed Tomography Computed Tomography , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/pathology , Embolization, Therapeutic/adverse effects , Female , Humans , Liver Circulation , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Male , Middle Aged , Predictive Value of Tests , Pulmonary Circulation , Radiation Dosage , Radiation Pneumonitis/diagnostic imaging , Radiation Pneumonitis/etiology , Radiopharmaceuticals/adverse effects , Retreatment , Retrospective Studies , Risk Assessment , Risk Factors , Technetium Tc 99m Aggregated Albumin/administration & dosage , Treatment OutcomeABSTRACT
Endometrial cancer is the most commonly diagnosed gynecological malignancy in developing countries, and the second malignancy after cervical cancer in developing countries. The primary treatment is based on surgical and pathologic staging including extrafascial type A radical hysterectomy bilateral salpingo-oophorectomy and pelvic and latero-aortic lymphadenectomy. Minimally invasive surgery is the most widely used technique. Sentinel node biopsy is part of this concept and has reached the management of endometrial cancer. The aim of this review was to describe the history, the different injection techniques and results of sentinel node biopsy, and analyze the future role of this technique in endometrial carcinoma.
Subject(s)
Endometrial Neoplasms/pathology , Sentinel Lymph Node Biopsy/methods , Sentinel Lymph Node/pathology , Colorimetry/methods , Coloring Agents , Endometrial Neoplasms/diagnostic imaging , Endometrial Neoplasms/surgery , Female , Humans , Hysterectomy/methods , Indocyanine Green/administration & dosage , Injections/methods , Lymph Node Excision/methods , Methylene Blue , Radiopharmaceuticals/administration & dosage , Rosaniline Dyes , Sentinel Lymph Node/diagnostic imaging , Sentinel Lymph Node Biopsy/trends , Spectroscopy, Near-Infrared , Technetium Tc 99m Aggregated Albumin/administration & dosageABSTRACT
PURPOSE: The development of erratic distribution of cervical metastases from oral cavity squamous cell carcinoma (OSCC) bypassing the typical metastatic pattern can possibly challenge the role of the classic neck dissection. The purpose of this study was to assess the role of lymphoscintigraphy (LS) and radio-guided neck dissection as a simple and widely accessible method with a favorable cost/benefit ratio, able to improve the OSCC staging and possibly to tailor the surgical approach to cervical lymph node dissection. METHODS: From June 2015 to December 2018, 16 patients (5 women, 11 men, median age 59.5±12.5 years) with cN0 (10) and cN+ (6) OSCC were enrolled. The day before surgery all patients underwent LS with acquisition of planar and SPECT (Single Photon Emission Computed Tomography)/CT images, after a peritumoral injection of 99mTc-Nanocoll® (median 74±1.2 MBq). Patients underwent tumor excision and a radioguided neck dissection, using a portable gamma camera. The sentinel lymph nodes (SLNs) were isolated and separately analyzed in 200-micron sections and pancytokeratin immunohistochemistry assessment, looking for micrometastases. RESULTS: A homolateral lymphatic spread on LS was observed in all cases, whereas in 5 cases (31.3%) lymphatic drainage was contralateral to the OSCC site. In one cN0 patient, a skip micrometastasis has been identified in a SLN. CONCLUSION: The results of the present study may suggest a role of LS and radioguided neck dissection in detecting the real lymphatic spread of OSCC, in order to improve the oncological assessment and to tailor the neck dissection.
Subject(s)
Mouth Neoplasms/diagnosis , Mouth Neoplasms/surgery , Sentinel Lymph Node/diagnostic imaging , Squamous Cell Carcinoma of Head and Neck/diagnosis , Squamous Cell Carcinoma of Head and Neck/surgery , Female , Humans , Lymph Node Excision/methods , Lymph Nodes/pathology , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/pathology , Lymphoscintigraphy/methods , Male , Middle Aged , Mouth Neoplasms/pathology , Neck Dissection/methods , Neoplasm Staging/methods , Radiopharmaceuticals/administration & dosage , Sentinel Lymph Node/pathology , Sentinel Lymph Node/surgery , Sentinel Lymph Node Biopsy/methods , Squamous Cell Carcinoma of Head and Neck/pathology , Technetium Tc 99m Aggregated Albumin/administration & dosage , Tomography, Emission-Computed, Single-Photon/methodsABSTRACT
This report describes a technique for measuring lung shunt fraction (LSF) twice in a single session during planning arteriography for radioembolization using low and standard dose technetium-99m macroaggregated albumin (99mTc-MAA). A patient with a 16.0 cm hepatocellular carcinoma and LSF of 70% was treated with lenvatinib for 4 weeks. Planning arteriography with administration of 0.5 millicuries of 99mTc-MAA was then performed. Arterial access was maintained while the LSF was calculated, which was persistently elevated at 54%. Embolization of arteriovenous shunts was performed during the same session and 5.0 millicuries of 99mTc-MAA were administered. The repeat LSF was 29%. Successful radioembolization was subsequently performed.
Subject(s)
Angiography , Embolization, Therapeutic , Liver Circulation , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/radiotherapy , Pulmonary Circulation , Radiopharmaceuticals/administration & dosage , Technetium Tc 99m Aggregated Albumin/administration & dosage , Aged , Humans , Liver Neoplasms/physiopathology , Male , Predictive Value of Tests , Treatment OutcomeABSTRACT
INTRODUCTION: The low accuracy of pre-operative imaging techniques for prediction of nodal status strengthens the relevance of sentinel lymph node (SLN) biopsy in endometrial cancer, although the optimal method for its detection is still under investigation. The increasing use of indocyanine green (ICG) has aroused concern about its enhanced visualization of lymphatic channels, which could lead to a specimen that is thought to be nodal tissue not subsequently yielding a lymph node on pathologic analysis ('empty node packet'). Our main objective was to compare the overall and bilateral detection rates for SLN biopsy using two combined techniques: technetium-99m-ICG (Tc-99m-ICG) versus technetium-99m-methylene blue (Tc-99m-MB). Our secondary aim was to compare the 'empty node packet' rates between the two cohorts. METHODS: A prospective, non-randomized, single-center trial including patients diagnosed with endometrial cancer (any grade or histology) in pre-operative early stage, and operated on between February 2017 and July 2019. All tracers were injected intracervically. Pelvic and aortic lymphadenectomy were performed on patients at intermediate or high risk of recurrence pre-operatively. All SLNs were sent for intra-operative frozen section and afterwards processed following an ultrastaging protocol. RESULTS: Eighty-four patients were included, 58% (n=49) in the Tc-99m-MB group and 42% (n=35) in the Tc-99m-ICG group. Overall detection rate was 93% and was not statistically different between the two groups. A better bilateral detection rate was observed among Tc-99m-ICG patients (69% vs 41%, p=0.012). The 'empty node packet' rate was 4% in the Tc-99m-ICG cohort and 0% in the Tc-99m-MB cohort (p=0.032). DISCUSSION: Tc-99m-ICG is a feasible, safe technique for SLN biopsy in early-stage endometrial cancer, and appears to be superior in terms of bilateral detection to Tc-99m-MB. The addition of Tc-99m to ICG could decrease the rate of 'empty node packets' and better define the anatomic location of SLNs in patients with endometrial cancer.
Subject(s)
Endometrial Neoplasms/pathology , Indocyanine Green/administration & dosage , Methylene Blue/administration & dosage , Sentinel Lymph Node Biopsy/methods , Sentinel Lymph Node/pathology , Technetium Tc 99m Aggregated Albumin/administration & dosage , Aged , Coloring Agents/administration & dosage , Endometrial Neoplasms/diagnostic imaging , Endometrial Neoplasms/surgery , Female , Humans , Middle Aged , Preoperative Care/methods , Radiopharmaceuticals/administration & dosage , Sentinel Lymph Node/diagnostic imaging , Sentinel Lymph Node/surgery , Single Photon Emission Computed Tomography Computed Tomography/methodsABSTRACT
Importance: The metastatic status of sentinel lymph nodes (SLNs) is the most relevant prognostic factor in breast cancer, melanoma, and other tumors. The conventional standard to label SLNs is lymphoscintigraphy with technetium Tc 99m. A worldwide shortage and known disadvantages of Tc 99m have intensified efforts to establish alternative, nonradioactive imaging techniques. Objective: To assess a new nonradioactive method using multispectral optoacoustic tomographic (MSOT) imaging in comparison with conventional lymphoscintigraphic imaging for SLN biopsy (SLNB) in melanoma. Design, Setting, and Participants: Analysis of a cross-sectional study was conducted at the University Hospital-Essen, Skin Cancer Center, Essen, Germany. Between June 2, 2014, and February 22, 2019, 83 patients underwent SLNB with an additional preoperative indocyanine green (ICG) application. Sentinel lymph node basins were preoperatively identified by MSOT imaging, and ICG-labeled SLNs were intraoperatively detected using a near-infrared camera. The surgeons were blinded to the lymphoscintigraphic imaging results in the beginning of the SLNB. Use of a γ probe was restricted until the SLNB procedure was attempted by the nonradioactive method. Main Outcomes and Measures: Concordance of SLN basins and SLNs identified by MSOT imaging plus near-infrared camera vs lymphoscintigraphic imaging plus single-photon emission computed tomographic or computed tomographic imaging was assessed. Results: Of the 83 patients (mean [SD] age, 54.61 [17.53] years), 47 (56.6%) were men. In 83 surgical procedures, 165 SLNs were excised. The concordance rate of ICG-labeled and Tc 99m-marked detected SLN basins was 94.6% (n = 106 of 112). Intraoperatively, 159 SLNs were detected using a near-infrared camera and 165 were detected by a γ probe, resulting in a concordance rate of 96.4%. Multispectral optoacoustic tomographic imaging visualized SLNs in all anatomic regions with high penetration depth (5 cm). Conclusions and Relevance: The findings of this study suggest that nonradioactive SLN detection via MSOT imaging allows identification of SLNs at a frequency equivalent to that of the current radiotracer conventional standard. Multispectral optoacoustic tomographic imaging appears to be a viable nonradioactive alternative to detect SLNs in malignant tumors.
Subject(s)
Lymphoscintigraphy/methods , Melanoma/pathology , Photoacoustic Techniques/methods , Sentinel Lymph Node Biopsy/methods , Adult , Aged , Coloring Agents/administration & dosage , Cross-Sectional Studies , Female , Humans , Indocyanine Green/administration & dosage , Male , Middle Aged , Radiopharmaceuticals/administration & dosage , Technetium Tc 99m Aggregated Albumin/administration & dosage , Tomography, X-Ray ComputedABSTRACT
Radioembolization with Yttrium-90 (Y90) has been proven safe and effective for the treatment of primary and secondary hepatic malignancies. Standard protocols have necessitated planning angiography with Technetium-99m macroaggregated albumin (Tc99m MAA) administration/scan typically 1-2 weeks prior to the radioembolization therapy. The intent of this practice is to ensure appropriate patient selection and treatment candidacy while also confirming best dosimetry approaches. At our center, we started performing "same-day Y90" in 2008; in a subset of international patients with travel hardship, we performed the planning and treatment procedures consecutively on the same day. In this article, we reveal our practical approach to treating patients on the same day as planning angiography. With more than 160 same-day procedures completed between 2008 and 2017, the safety and efficacy of such a paradigm has been established at our center. This approach is appealing to patients, their families, and referring physicians. Appropriate patient selection and proper preprocedure planning based on baseline imaging are key elements in successful same-day radioembolization treatments.
Subject(s)
Ambulatory Care/methods , Carcinoma, Hepatocellular/radiotherapy , Embolization, Therapeutic/methods , Liver Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Aged , Angiography/methods , Carcinoma, Hepatocellular/diagnostic imaging , Female , Humans , Imaging, Three-Dimensional , Liver Neoplasms/diagnostic imaging , Male , Microspheres , Patient Selection , Radiopharmaceuticals/administration & dosage , Radiotherapy Dosage , Technetium Tc 99m Aggregated Albumin/administration & dosage , Treatment OutcomeABSTRACT
This paper describes a new nuclear imaging agent, 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid of human albumin (HAC), potentially suitable for application in the Radio-guided Occult Lesion Localization (ROLL) of non-palpable mammalian cancerous lesions, as a tool to overtake the short radio-signal half-life of the technetium-99m based radiopharmaceutical currently used. This conjugate is a microsized powder aggregate, water-insoluble between pH 3 and 8.5, obtained by conjugating the protein with the macrocyclic chelating agent DOTA through a one-pot reaction in aqueous medium. The product has been fully characterized and is stable to the thermal conditions adopted for labeling; after radiolabeling with longer half-life radionuclides such as 177Lu or 111In, it has shown radiochemical purity (RCP) >90% and resulted stable when stored in saline or plasma for 6 days at 37 °C. A µPET/CT study, performed in vivo on adult female rats, showed that the radioactivity of HAC labeled with 64Cu remained located in the mammary glands for at least 40 h, without diffusion or drainage in healthy tissues or in the lymphatic circulation. This new imaging agent might make the ROLL procedure more accessible, safe and flexible, promoting a significant time and cost reduction of this intervention. Moreover, HAC might also be used in other radio-guided surgical procedures in oncology.
Subject(s)
Breast Neoplasms/diagnostic imaging , Heterocyclic Compounds/chemistry , Isothiocyanates/chemistry , Radionuclide Imaging/methods , Albumins/administration & dosage , Animals , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Heterocyclic Compounds/administration & dosage , Heterocyclic Compounds/pharmacology , Isothiocyanates/administration & dosage , Isothiocyanates/pharmacology , Microspheres , Radiopharmaceuticals , Rats , Sentinel Lymph Node Biopsy/methods , Surgery, Computer-Assisted/methods , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Aggregated Albumin/chemistry , Technetium Tc 99m Aggregated Albumin/pharmacologyABSTRACT
PURPOSE: Selective internal radiation therapy (SIRT) is an effective treatment option for liver tumors, using Y-90-loaded polymer microspheres that are delivered via catheterization of the hepatic artery. Since Y-90 is a beta emitter and not conveniently imaged by standard clinical instrumentation, dosimetry is currently evaluated in each patient using a surrogate particle, 99mTechnetium-labeled macroaggregated albumin (99mTc-MAA). We report a new composite consisting of 99mTc-labeled nanoparticles attached to the same polymer microspheres as used for SIRT, which can be imaged with standard SPECT. METHODS: Carbon nanoparticles with an encapsulated core of 99mTc were coated with the polycation protamine sulfate to provide electrostatic attachment to anionic polystyrene sulfonate microspheres of different sizes (30, 12, and 8 µm). The in vivo stability of these composites was determined via intravenous injection and entrapment in the capillary network of normal rabbit lungs for up to 3 hours. Furthermore, we evaluated their biodistribution in normal rabbit livers, and livers implanted with VX2 tumors, following intrahepatic artery instillation. RESULTS: We report distribution tests for three different sizes of radiolabeled microspheres and compare the results with those obtained using 99mTc-MAA. Lung retention of the radiolabeled microspheres ranged from 72.8% to 92.9%, with the smaller diameter microspheres showing the lowest retention. Liver retention of the microspheres was higher, with retention in normal livers ranging from 99.2% to 99.8%, and in livers with VX2 tumors from 98.2% to 99.2%. The radiolabeled microspheres clearly demonstrated preferential uptake at tumor sites due to the increased arterial perfusion produced by angiogenesis. CONCLUSION: We describe a novel use of radiolabeled carbon nanoparticles to generate an imageable microsphere that is stable in vivo under the shear stress conditions of arterial networks. Following intra-arterial instillation in the normal rabbit liver, they distribute in a distinct segmented pattern, with the smaller microspheres extending throughout the organ in finer detail, while still being well retained within the liver. Furthermore, in livers hosting an implanted VX2 tumor, they reveal the increased arterial perfusion of tumor tissue resulting from angiogenesis. These novel composites may have potential as a more representative mimic of the vascular distribution of therapeutic microspheres in patients undergoing SIRT.
Subject(s)
Arteries/diagnostic imaging , Liver Neoplasms/blood supply , Liver Neoplasms/diagnostic imaging , Liver/blood supply , Lung/blood supply , Microspheres , Technetium/chemistry , Animals , Cell Line, Tumor , Female , Injections, Intra-Arterial , Injections, Intravenous , Liver/diagnostic imaging , Liver Neoplasms/drug therapy , Lung/diagnostic imaging , Male , Polystyrenes/chemistry , Rabbits , Radiopharmaceuticals/chemistry , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Aggregated Albumin/chemistry , Tissue Distribution , Treatment OutcomeABSTRACT
BACKGROUND: Hepatopulmonary syndrome (HPS) is defined as a triad characterized by arterial deoxygenation, intrapulmonary vascular dilatations (IPVDs), and liver disorder. The aims of this study were to assess the prevalence of HPS in children with cirrhosis, the clinical characteristics of patients with HPS, and the tests used for the diagnosis of IPVD. PATIENTS AND METHODS: This was a prospective, cross-sectional study of 40 children with cirrhosis (median age: 44 months). Investigations of HPS included arterial blood gas analysis, contrast-enhanced transthoracic echocardiography (CE-TTE), and perfusion lung scanning using technetium-99m-labeled macroaggregated albumin (Tc-MMA). Patients' clinical characteristics (age, etiology of cirrhosis, and severity of hepatopathy) were assessed. HPS was defined as liver disease; alveolar-arterial oxygen gradient of at least 15 mmHg and/or partial pressure of arterial oxygen less than 80 mmHg; and detection of IPVD by CE-TTE or Tc-MMA scanning. Statistical significance was indicated by a P value less than 0.05. RESULTS: The prevalence of HPS was 42.5% (17/40). Eight patients had moderate HPS (47%) and two patients had severe HPS (12%). In bivariate analysis, biliary atresia (P=0.033) and median age (10 months; P=0.005) were associated with HPS. In multivariate analysis, only age remained statistically significant (prevalence ratio=0.99; 95% confidence interval=0.98-0.99; P=0.010). Sixteen patients with HPS had IPVD detected by CE-TTE (94.1%) and six patients had IPVD detected by Tc-MMA scanning (35.3%), with no significant agreement between these methods (κ=-0.12; P=0.163). CONCLUSION: HPS is a common complication of cirrhosis in children. A combination of clinical and imaging criteria should be used to diagnose HPS.
Subject(s)
Hepatopulmonary Syndrome/epidemiology , Liver Cirrhosis/epidemiology , Adolescent , Age Factors , Blood Gas Analysis , Brazil/epidemiology , Child , Child, Preschool , Cross-Sectional Studies , Echocardiography , Female , Hepatopulmonary Syndrome/diagnostic imaging , Hepatopulmonary Syndrome/physiopathology , Humans , Infant , Liver Cirrhosis/diagnosis , Liver Cirrhosis/physiopathology , Male , Perfusion Imaging/methods , Predictive Value of Tests , Prevalence , Prognosis , Prospective Studies , Radiopharmaceuticals/administration & dosage , Risk Factors , Severity of Illness Index , Technetium Tc 99m Aggregated Albumin/administration & dosageABSTRACT
BACKGROUND: We evaluated the clinical significance of follow-up data, including 99mTc-DTPA galactosyl human serum albumin (99mTc-GSA) liver scintigraphy data, as prognostic indicators for jaundice-free patients with biliary atresia (BA). METHODS: Of 87 patients who underwent Kasai portoenterostomy (KP) between 1991 and 2012, 45 jaundice-free patients aged 1-2â¯years underwent 99mTc-GSA scintigraphy and were classified into 2 groups: those who survived with a native liver (Group A, nâ¯=â¯34) and those who required liver transplantation (LTx) (Group B, nâ¯=â¯11). We compared 99mTc-GSA scintigraphy data (HH15, LHL15, and HH15/LHL15 [H/L15]) and liver function test (LFT) results between the groups. The patients underwent a second 99mTc-GSA scintigraphy at approximately 5â¯years of age. RESULTS: All patients survived. HH15, H/L15, total bilirubin, direct bilirubin, gamma-glutamyl transpeptidase, and alanine transaminase levels were higher in Group B than in Group A (p<0.05). Total and direct bilirubin levels were associated with H/L15 (p<0.05). There were no significant changes in results between the first and second 99mTc-GSA scintigraphy in Group A. CONCLUSIONS: Mid- and long-term prognoses may be predicted using 99mTc-GSA scintigraphy data and LFTs in patients aged 1-2â¯years. We recommend regular monitoring of postoperative data following KP, even in jaundice-free patients. LEVEL OF EVIDENCE: III.
Subject(s)
Biliary Atresia/diagnostic imaging , Liver/diagnostic imaging , Pentetic Acid/administration & dosage , Technetium Tc 99m Aggregated Albumin/administration & dosage , Biliary Atresia/surgery , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Jaundice , Liver Function Tests/methods , Liver Transplantation/statistics & numerical data , Male , Portoenterostomy, Hepatic/statistics & numerical data , Prognosis , Radionuclide Imaging/methodsABSTRACT
99mTc-labeled mannosylated human serum albumin (MSA) has been reported as a sentinel lymph node (SLN)-imaging agent by binding to macrophages in the LNs. By conjugating it with blue dye, we developed a new multimodal radio-nanocarrier by visual investigation, fluorescence imaging, and single photon emission computed tomography (SPECT)/computed tomography (CT). Binding affinities of seven blue dyes to MSA were tested. According to the spectroscopic study and visual inspection of MSA-bound dyes, naphthol blue black (NBB) was selected as the best candidate of multimodal agent. Thus, 99mTc-MSA-NBB conjugate was prepared and further investigated using mice. After footpad injection, it showed high popliteal LN accumulation at 1 h. SPECT/CT also showed high popliteal as well as inguinal LN uptakes at 10 min that sustained until 2 h. In conclusion, we prepared a multimodal SLN imaging radio-nanocarrier, 99mTc-MSA-NBB conjugate, and confirmed its excellency as a multimodal probe for SLN mapping.
Subject(s)
Macrophages/drug effects , Nanoparticles/administration & dosage , Sentinel Lymph Node/diagnostic imaging , Single Photon Emission Computed Tomography Computed Tomography , Animals , Azo Compounds/chemistry , Female , Humans , Mice , Middle Aged , Nanoparticles/chemistry , Naphthalenesulfonates/chemistry , Sentinel Lymph Node/physiology , Sentinel Lymph Node Biopsy , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Aggregated Albumin/chemistryABSTRACT
Objetivo. Evaluar la reproductibilidad de la técnica del ganglio centinela (GC) en el cáncer de mama en el varón. Material y métodos. Analizamos retrospectivamente a 21 pacientes varones diagnosticados de cáncer de mama en nuestro hospital desde 2008 hasta 2016, con un seguimiento de al menos 18 meses. A 15 pacientes se les realizó la biopsia selectiva de ganglio centinela (BSGC) siguiendo los protocolos habituales con inyección de 74-111MBq de 99mTc-nanocoloides peritumoral y adquisición de imágenes planares a las 2h. En 2 casos fue necesaria la realización de SPECT/TC para la localización del GC. Para su análisis se usaron técnicas anatomopatológicas de inmunohistoquímica o técnicas moleculares (OSNA). Seis pacientes no se sometieron a la BSGC por presentar ganglios patológicos o enfermedad a distancia en el momento del diagnóstico. Resultados. La BSGC se practicó en 15 pacientes. El GC fue negativo en 6 de estos, siendo positivo en los 9 restantes. Hubo 3 pacientes con BSGC positiva, pero dado el bajo número de copias de ADN (OSNA) no se realizó linfadenectomía axilar. Sí se llevó a cabo vaciamiento axilar en los 6 pacientes restantes, con resultado de 4 vaciamientos positivos y 2 que no mostraban extensión de la enfermedad. Conclusiones. Según nuestra experiencia, la BSGC en los varones es una técnica reproducible, útil, segura y fiable, que evita la realización de linfadenectomías axilares innecesarias y previene la aparición de efectos no deseados
Objective. To evaluate the reproducibility of the sentinel lymph node (SLN) technique in male breast cancer. Material and methods. We retrospectively analysed 21 male patients diagnosed with breast cancer in our hospital from 2008 to 2016 with, at least, 18 months follow-up. Fifteen patients underwent selective sentinel lymph node biopsy (SLNB) following the usual protocols with peritumoral injection of 18.5-111MBq of 99mTc-nanocoloides and acquisition of planar images 2hours after the injection. In 2 cases it was necessary to perform a SPECT/CT to locate the SLN. Immunohistochemistry and molecular techniques (OSNA) were used for their analysis. Six patients did not undergo SLNB because they had pathological nodes or distant disease at the time of diagnosis. Results. SLNB was performed in 15 patients. The SLN was negative in 6 patients and positive in the remaining 9. Three patients with positive SLNB did not need axillary lymphadenectomy because of the low number of copies by molecular analysis OSNA. Axillary lymphadenectomy was performed in the remaining 6 patients with the result of 4 positive axillary lymphadenectomies and 2 that did not show further extension of the disease. Conclusions. According to our experience, SLNB in males is a reproducible, useful, safe and reliable technique which avoids unnecessary axillary lymphadenectomy and prevents the appearance of undesirable effects